Last 12 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -21.21 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.39 | 3.98 | 4.10 | 3.23 | 3.49 | 4.54 | 2.87 | 4.16 | 3.73 | 2.64 | — | — | — |
| — | -12.3% | +42.5% | -22.4% | -6.4% | +72.2% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -33.2% | -10.8% | -10.2% | -8.0% | -9.3% | -6.5% | -4.3% | -5.4% | -8.0% | -8.0% | -15.5% | -9.2% | -9.9% |
| — | -65.9% | -138.1% | -46.5% | -15.2% | +18.5% | +72.3% | +40.8% | +18.4% | — | — | — | — | |
| ROA | -31.5% | -10.1% | -9.6% | -7.5% | -8.8% | -6.2% | -4.2% | -5.2% | -7.7% | -7.5% | -13.9% | -8.5% | -9.2% |
| — | -62.9% | -131.4% | -43.9% | -14.6% | +16.9% | +69.9% | +38.5% | +16.8% | — | — | — | — | |
| ROIC | -38.3% | -10.8% | -10.1% | -8.1% | -9.4% | -8.0% | -8.4% | -9.9% | -11.5% | -17.4% | — | — | — |
| — | -34.1% | -20.5% | +17.5% | +18.5% | +54.1% | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — | — |
| — | +1.7% | +231.7% | +694.0% | +208.3% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 18.55 | 15.86 | 16.36 | 15.82 | 18.55 | 16.39 | 27.70 | 38.08 | 19.38 | 24.82 | 7.42 | 12.69 | 15.24 |
| — | -3.2% | -40.9% | -58.4% | -4.3% | -34.0% | +273.4% | +200.1% | +27.2% | — | — | — | — | |
| Quick Ratio | 18.55 | 15.86 | 16.36 | 15.82 | 18.55 | 16.39 | 27.70 | 38.08 | 19.38 | 24.82 | 7.42 | 12.69 | 15.24 |
| — | -3.2% | -40.9% | -58.4% | -4.3% | -34.0% | +273.4% | +200.1% | +27.2% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonApogee Therapeutics, Inc.'s current P/E is -21.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Apogee Therapeutics, Inc.'s business trajectory between earnings reports.